AstraZeneca pulls Imfinzi in bladder cancer, nearly one year after Phase 3 miss

Urinary system, bladder, kidney

AstraZeneca is withdrawing U.S. marketing of Imfinzi in bladder cancer after the drug failed a study required as a condition of its 2017 accelerated approval. The drug’s other approvals in lung cancer are not affected.